Search

Recursion Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

4 -8.26

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.93

Massimo

4.36

Metriche Chiave

By Trading Economics

Entrata

-14M

-131M

Vendite

1.2M

7.7M

EPS

-0.25

Margine di Profitto

-1,708.018

Dipendenti

600

EBITDA

-10M

-113M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+52.52% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

876M

2.6B

Apertura precedente

12.26

Chiusura precedente

4

Recursion Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 ott 2026, 20:02 UTC

Recursion Pharmaceuticals Inc shares are sharply lower, continuing a downward trend since Friday, despite an early spike in today's trading session.

10 ott 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced during after-market hours on Friday, despite earlier pulling back from a session high.

9 ott 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from an earlier decline while remaining well above its 20-day moving average.

8 ott 2026, 20:01 UTC

News
Correlated Moves

Recursion Pharmaceuticals faces downward pressure amid significant insider transactions, including a 50k share sale by Director Borgeson Blake on October 6.

7 ott 2026, 23:05 UTC

Recursion Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower since Wednesday's close.

6 ott 2026, 20:02 UTC

Correlated Moves
Social Media
News

Recursion Pharmaceuticals Inc. shares fell amid sector declines, with attention on upcoming Phase 2 data for REC-4881 and ongoing trials for other candidates.

5 ott 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, continuing lower since Monday's close, despite remaining above its 20-day moving average.

2 ott 2026, 20:07 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading higher, supported by a favorable market environment and positive sentiment following recent labor statistics.

1 ott 2026, 23:01 UTC

Recursion Pharmaceuticals Inc saw modest gains in after-market hours, reaching a peak increase before settling lower, remaining near the upper end of its one-month range.

30 set 2026, 23:30 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading higher in after-market hours, reflecting a broader market trend amid positive developments in technology and a revised U.S. GDP growth rate.

29 set 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares declined modestly in after-market trading, moving lower from Tuesday's close, currently around 0.74%, but above its 20-day moving average.

28 set 2026, 19:35 UTC

Social Media

Recursion Pharmaceuticals Inc shares fell amid commentary on its role in AI-driven drug design, reflecting a decline since Friday's close.

25 set 2026, 23:50 UTC

Recursion Pharmaceuticals Inc has advanced in after-market trading, remaining above its 20-day moving average and near the upper end of its one-month trading range.

24 set 2026, 20:07 UTC

Correlated Moves

Recursion Pharmaceuticals is advancing amid a positive biotechnology trend, gaining alongside the ARK Genomic Revolution ETF, which benefits from favorable news from its holdings.

23 set 2026, 23:21 UTC

Recursion Pharmaceuticals Inc is advancing in after-market trading, rising sharply since Wednesday's close and remaining above its 20-day moving average.

22 set 2026, 19:50 UTC

Social Media

Recursion Pharmaceuticals' stock is advancing after extending a data license agreement with Tempus AI, involving $42 million in committed payments over three years.

21 set 2026, 23:30 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, contrasting with recent gains, though it remains above its 20-day moving average.

19 set 2026, 00:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, moving lower since Friday's close, with notable momentum shifts observed during the session.

18 set 2026, 23:41 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, moving lower since Friday's close, despite remaining significantly above its 20-day moving average.

17 set 2026, 23:01 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading modestly lower in after-market hours, moving in sympathy with Schrodinger Inc amid mixed economic indicators.

16 set 2026, 22:51 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is moving higher in after-market trading, reflecting broader market gains following a sharp rise in U.S. retail sales in August.

15 set 2026, 23:02 UTC

Recursion Pharmaceuticals Inc. shares are higher in after-market trading, following the broader market's upward trend despite no specific company news.

14 set 2026, 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is gaining today, benefiting from Schrödinger's collaboration agreement with Tectora Therapeutics. Earlier, shares pulled back but have since recovered.

11 set 2026, 19:46 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, despite a slight pullback from earlier highs. No specific news was identified for the move.

10 set 2026, 23:16 UTC

No specific news was identified for Recursion Pharmaceuticals Inc. during after-market hours. The stock remained roughly flat since Thursday's close.

9 set 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading, following a notable peak earlier in the session with no specific news identified.

8 set 2026, 22:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading. The stock remains above its 20-day moving average and near the upper end of its one-month range.

4 set 2026, 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 set 2026, 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 set 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

Confronto tra pari

Modifica del prezzo

Recursion Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

52.52% in crescita

Previsioni per 12 mesi

Media 6.65 USD  52.52%

Alto 8 USD

Basso 5.3 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Recursion Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

2

Acquista

3

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.